Nogimori T, Braverman L E, Taurog A, Fang S L, Wright G, Emerson C H
Endocrinology. 1986 Apr;118(4):1598-605. doi: 10.1210/endo-118-4-1598.
After in vivo administration, propylthiouracil (PTU) inhibits not only thyroid iodide uptake and organification, but also T4 5'-deiodinase activity in most peripheral organs. The present report describes the effects of some previously untested 6-substituted 2-thiouracil derivatives on in vivo and in vitro iodide uptake and organification, and on T4 5'-deiodinase activity in liver and pituitary homogenates. When added to homogenates, many analogs were as potent or more potent than PTU in inhibiting hepatic T4 5'-deiodinase activity. Three derivatives, 6-anilino-2-thiouracil (A compound), 6-(p-ethylanilino)2-thiouracil (B compound), and 6-(p-n-butylanilino) 2-thiouracil (C compound), which were among the most potent inhibitors of hepatic T4 5'-deiodinase, when added in vitro inhibited T4 5'-deiodinase activity in liver homogenates after in vivo administration. When added to pituitary homogenates prepared from hypothyroid rats, these compounds also significantly inhibited pituitary T4 5'-deiodinase activity. In a concentration of 1 mM in the presence of 20 mM dithiothreitol, the percent inhibition of pituitary T4 5'-deiodinase activity was 19.7 +/- 7.4 (mean +/- SE), 34.0 +/- 3.2, 47.3 +/- 3.1, and 89.0 +/- 1.0 for PTU and the A, B, and C compounds, respectively (P less than 0.05 for all groups vs. one another and vehicle). Despite their ability to inhibit hepatic T4 5'-deiodinase activity, none of the 13 analogs tested altered thyroid iodide uptake or organification after administration of 0.1 mg/rat. PTU, in the same dose, inhibited thyroid iodide uptake by 78.2 +/- 2.4% (P less than 0.001) and thyroid iodide organification by 36.4 +/- 7.3% (P less than 0.01). Furthermore, the A, B, and C compounds did not inhibit thyroid iodide uptake or iodide organification when administered in higher doses of 5, 5, and 1 mg/rat, respectively. In contrast to these in vivo results, the A, B, and C compounds were more potent than PTU in inhibiting iodide organification in a purified thyroid peroxidase system and in porcine thyroid slices. The concentrations causing 50% inhibition of iodide organification in the purified thyroid peroxidase system were 30, 7, 8, and 14 microM for PTU and the A, B, and C compounds, respectively. However, PTU was far more potent in inhibiting iodide organification in intact incubated thyroid lobes compared to the A, B, and C compounds.(ABSTRACT TRUNCATED AT 400 WORDS)
体内给药后,丙硫氧嘧啶(PTU)不仅抑制甲状腺对碘的摄取和有机化,还抑制大多数外周器官中的T4 5'-脱碘酶活性。本报告描述了一些先前未经测试的6-取代2-硫脲嘧啶衍生物对体内和体外碘摄取及有机化,以及对肝脏和垂体匀浆中T4 5'-脱碘酶活性的影响。当添加到匀浆中时,许多类似物在抑制肝脏T4 5'-脱碘酶活性方面与PTU一样有效或更有效。三种衍生物,6-苯胺基-2-硫脲嘧啶(A化合物)、6-(对-乙基苯胺基)2-硫脲嘧啶(B化合物)和6-(对-正丁基苯胺基)2-硫脲嘧啶(C化合物),它们是肝脏T4 5'-脱碘酶的最有效抑制剂之一,在体外添加时可抑制体内给药后肝脏匀浆中的T4 5'-脱碘酶活性。当添加到由甲状腺功能减退大鼠制备的垂体匀浆中时,这些化合物也显著抑制垂体T4 5'-脱碘酶活性。在1 mM浓度且存在20 mM二硫苏糖醇的情况下,PTU以及A、B和C化合物对垂体T4 5'-脱碘酶活性的抑制百分比分别为19.7±7.4(平均值±标准误)、34.0±3.2、47.3±3.1和89.0±1.0(所有组之间以及与溶剂相比P均小于0.05)。尽管它们有能力抑制肝脏T4 5'-脱碘酶活性,但在以0.1 mg/大鼠给药后,所测试的13种类似物均未改变甲状腺对碘的摄取或有机化。相同剂量的PTU抑制甲状腺对碘的摄取达78.2±2.4%(P小于0.001),抑制甲状腺碘有机化达36.4±7.3%(P小于0.01)。此外,分别以5、5和1 mg/大鼠的更高剂量给药时,A、B和C化合物也不抑制甲状腺对碘的摄取或碘有机化。与这些体内结果相反,A、B和C化合物在纯化的甲状腺过氧化物酶系统和猪甲状腺切片中比PTU更有效地抑制碘有机化。在纯化的甲状腺过氧化物酶系统中导致碘有机化50%抑制的浓度,PTU以及A、B和C化合物分别为30、7、8和14 microM。然而,与A、B和C化合物相比,PTU在完整孵育的甲状腺叶中抑制碘有机化的能力要强得多。(摘要截短至400字)